v3.26.1
FAIR VALUE MEASUREMENTS - Additional Information (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Jun. 20, 2023
USD ($)
Jul. 01, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Fair value of debt $ 5,600,000,000   $ 5,600,000,000   $ 5,700,000,000    
Invigorate Program              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Restructuring and impairment charges 2,000,000 $ 25,000,000 9,000,000 $ 36,000,000      
Income Statement Location [Axis]: us-gaap:CostOfRevenue | Invigorate Program              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Restructuring and impairment charges       6,000,000      
Income Statement Location [Axis]: us-gaap:OtherOperatingIncomeExpenseNet | Invigorate Program              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Restructuring and impairment charges   24,000,000   24,000,000      
Income Statement Location [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Invigorate Program              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Restructuring and impairment charges   $ 1,000,000   $ 6,000,000      
UMass Joint Venture              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Ownership percentage by noncontrolling owners             18.90%
Fair Value, Inputs, Level 3 | Contingent Consideration              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Total fair value adjustments included in earnings - realized/unrealized     4,000,000        
Liability 100,000,000   100,000,000   96,000,000    
Fair Value, Inputs, Level 3 | Contingent Consideration | Balance Sheet Location [Axis]: us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Liability 51,000,000   51,000,000   51,000,000    
Fair Value, Inputs, Level 3 | Contingent Consideration | Balance Sheet Location [Axis]: us-gaap:OtherLiabilities              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Liability $ 49,000,000   $ 49,000,000   $ 45,000,000    
Haystack Oncology, Inc. | Comparable Company Revenue Volatility              
Business Combination [Line Items]              
Measurement input 0.25   0.25        
Haystack Oncology, Inc. | Discount rate              
Business Combination [Line Items]              
Measurement input 0.070   0.070        
Haystack Oncology, Inc. | Additional, Based on Revenue              
Business Combination [Line Items]              
Maximum contingent consideration payment           $ 100,000,000  
Haystack Oncology, Inc. | Additional, Reimbursement Coverage              
Business Combination [Line Items]              
Maximum contingent consideration payment           $ 50,000,000  
Haystack Oncology, Inc. | Additional Impact | Discount rate              
Business Combination [Line Items]              
Measurement input 0.05   0.05        
Haystack Oncology, Inc. | Changing Comparable Company Revenue Volatility | Comparable Company Revenue Volatility              
Business Combination [Line Items]              
Measurement input 0.30   0.30        
Increase in contingent consideration liability $ 3,000,000            
Haystack Oncology, Inc. | Changing Discount Rate | Comparable Company Revenue Volatility              
Business Combination [Line Items]              
Increase in contingent consideration liability $ 4,000,000            
Haystack Oncology, Inc. | Changing Discount Rate | Discount rate              
Business Combination [Line Items]              
Measurement input 0.105   0.105